LabHub

Blog

AI Telehealth & Remote Care 2026 Complete Guide - Teladoc, Amwell, Hims & Hers, Ro, K Health, DoctorNow, Goodoc, Ttocdoc, Linkx, LINE Healthcare, MedPeer Deep Dive

2026-05-16 · 29 min read · #telehealth#remote-care#teladoc#amwell#hims-hers#ro-health#k-health#doktorna-now#doctolib#linkx#line-healthcare#medpeer#english

한국어English日本語

Prologue — Telehealth Enters Its Mature Phase in 2026

The COVID-19 pandemic in March 2020 thrust telehealth into the mainstream overnight. The US CMS (Centers for Medicare and Medicaid Services) lifted Medicare telehealth restrictions on a temporary basis as of March 17, 2020, Korea allowed temporary non-face-to-face care on February 24, 2020, and Japan allowed online consultations from a first visit on April 2, 2020.

Six years later, in May 2026, those temporary measures have either become permanent or been partly rolled back. The US Medicare telehealth extension nearly expired in March 2025 but Congress extended it to September 2025, and then a second extension carried it to September 2026. Korea moved from a pilot program in June 2023 to a December 2024 partial amendment of the Medical Service Act, centering on chronic-disease management and follow-up care. Japan elevated its online consultation guidelines to a main provision in January 2022 and put online prescriptions into effect in April 2023.

A one-sentence snapshot of telehealth as of May 2026:

This essay ties together the pricing, clinical evidence, regulation, and real usage scenarios of those 70-plus services in a single flow.

Chapter 1 · Why Telehealth Did Not Work Before 2020

Telehealth existed for more than 30 years before COVID-19. NASA tried it in 1989 for astronaut medicine, and military medics used satellite links for remote consultations in the 1990s. It failed to spread to ordinary citizens for three reasons.

In March 2020, CMS lifted all three at once with the 1135 Waiver. Medicare recognized urban patients, state license limits were temporarily lifted, and non-HIPAA Zoom, FaceTime, and Skype were allowed. Telehealth claims grew 154-fold in a single month in April 2020 (HHS OIG report).

Korea moved from temporary permission on February 24, 2020 to a pilot program in June 2023 and the December 2024 amendment of the Medical Service Act. Japan moved consistently: first-visit allowance on April 2, 2020, main-provision elevation in January 2022, and online prescriptions in April 2023.

[Telehealth evolution timeline — 2020-2026]
  2020-03  US CMS 1135 Waiver, Korea emergency allowance, Japan first-visit allowance
  2020-08  Teladoc + Livongo merger announced ($18.5B)
  2021-01  Hims & Hers SPAC IPO (NYSE:HIMS)
  2021-05  Cerebral Series C ($1.5B valuation), ADHD prescriptions explode
  2022-01  Japan online consultation main-provision elevation
  2022-04  Done. DOJ investigation, Cerebral DEA investigation begins
  2023-04  Japan online prescription enforcement
  2023-06  Korea non-face-to-face care pilot launches
  2023-08  Babylon Health UK subsidiary goes bankrupt
  2024-04  Hims & Hers compounded GLP-1 launch
  2024-12  Korea Medical Service Act amendment (chronic & follow-up expansion)
  2025-09  US Medicare telehealth extension (to 2026-09)

Chapter 2 · The US Telehealth Leader — Teladoc Health (NYSE:TDOC)

Teladoc Health (teladochealth.com) was founded in Texas in 2002 and is the largest US telehealth company. It went public on NYSE in July 2015. As of May 2026, its market cap is about $1.7 billion, down roughly 95 % from its 2021 peak of $308.

Pricing is dominated by payer and employer channels. One-off visits paid out of pocket cost about $75, and the BetterHelp mental health subscription runs $65-100 per week.

Teladoc's core asset is chronic-disease management. The Livongo-integrated diabetes and hypertension devices (BG meters, BP monitors) and data platform together remain the largest chronic-care pool in US telehealth in 2026.

Chapter 3 · Amwell (American Well) — Hospital Partnership Pivot

American Well (americanwell.com, NYSE:AMWL) was founded in Boston in 2006 by brothers Roy and Ido Schoenberg. It went public on NYSE in September 2020, raising about $700 million.

Amwell's strategy diverges from Teladoc's. Teladoc tried to capture both B2C (direct to patient) and B2B2C (through payers), while Amwell chose to be the white-label infrastructure for hospitals and health systems. So the "Amwell" brand is weak with ordinary consumers, but over 100 US health systems use Amwell as the back end for their patient apps.

Chapter 4 · MDLive (Cigna Evernorth) — Payer Integration

MDLive (mdlive.com) is one of the earliest US telehealth firms, founded in the late 1990s and acquired by Cigna's Evernorth subsidiary for about $500 million in April 2021. Since then, MDLive has been integrated as the digital health channel for Cigna Healthcare members rather than as a standalone telehealth brand.

MDLive's value is being "the most cleanly payer-integrated telehealth." Surviving as a standalone brand was hard in the early 2020s, but inside Cigna it has the cleanest infrastructure for simplifying payment, billing, and automatic enrollment.

Chapter 5 · Doctor on Demand + Grand Rounds → Included Health

Included Health (includedhealth.com) was born in March 2021 from the merger of Doctor on Demand and Grand Rounds Health. Both companies had been founded in the early 2010s.

Included Health's differentiator is medical navigation. In the US system, deciding "which specialist to see and where" is surprisingly hard. The Grand Rounds legacy lives on in automating that matching and second-opinion service.

Chapter 6 · Hims & Hers Health (NYSE:HIMS) — Exploded on GLP-1

Hims & Hers Health (hims.com, forhers.com) was founded by Andrew Dudum in November 2017 and is the flagship of DTC (direct-to-consumer) telehealth.

What sets Hims & Hers apart is "not going through insurance." It simplifies prices in the cash market and ships medications directly. The April 2024 compounded GLP-1 launch (503A pharmacies filling the Eli Lilly and Novo Nordisk shortage) doubled revenue, but the legal foundation for compounding shook when the FDA declared the semaglutide shortage resolved in October 2024.

In April 2025, it signed a direct supply deal with Novo Nordisk to shift to legitimate Wegovy prescriptions, and prices were partially raised from $199.

Chapter 7 · Ro (Roman + Plenity + Modern Fertility) — Men's Full Stack

Ro (ro.co, originally Roman Health) was founded in 2017 by Zachariah Reitano, Saman Rahmanian, and Rob Schutz. It began as a single-line tele-ED (erectile dysfunction) business under the Roman brand.

Ro is private (not listed). It reached a $7 billion valuation in March 2022 with a $1.4 billion Series D, but value wobbled after intensifying GLP-1 competition and compounding regulatory risk.

Ro's strength is the depth of its men's market. The Roman brand works as a comprehensive male primary-care channel from ED to hair loss to cholesterol to diabetes.

Chapter 8 · K Health — AI Symptom Checker Plus GP

K Health (khealth.com) was founded in 2016 in Tel Aviv, Israel, by Allon Bloch and co-founders. It is dual-headquartered in the US and Israel.

K Health's core is that the AI symptom checker is a diagnostic model, not a simple chatbot. Patient symptom input → statistical match to past patients of the same symptoms, age, and sex → primary triage handed to the physician. The company claims it cuts average physician visit time in half.

Chapter 9 · Sesame — Flat-Rate Marketplace

Sesame (sesamecare.com) was founded by David Goldhill and Michael Botta in 2018 with the motto "see a doctor at a reasonable price even without insurance."

Sesame's value is price transparency. It shows the biggest pain point of US healthcare — "you don't know how much it will cost" — on the first screen. Without insurance reconciliation, there is also less retrospective-billing risk for physicians.

Chapter 10 · PlushCare (Accolade), Talkiatry, Cerebral — Specialty Branching

While legacy telehealth tried to capture all of primary care, the mid-2020s saw branching into specialties.

Cerebral and Done. illustrate the regulatory gray zone of telehealth. Remote prescribing of controlled substances (Schedules II, III, IV) was originally governed by the 1973 Ryan Haight Act with an in-person-visit requirement, temporarily lifted during COVID. The DEA Final Rule in November 2025 made some of that permanent, but ADHD medications remain under strict limits.

Chapter 11 · Mental Health Telehealth — Talkspace, BetterHelp, Lyra, Spring, Headspace, Brightline

Mental health is the category where telehealth works best. No stethoscope or labs are needed, and conversation is the substance of care.

The 2024-2025 trend shifted from B2C to B2B (employer insurance). Employees get free sessions through their EAP (Employee Assistance Program), then continue with insurance-billed care. Lyra and Spring are the two leaders in that space.

Chapter 12 · AI Medical Scribes — Abridge, Suki, Microsoft Nuance DAX

Physicians spending 30 minutes to two hours per visit on charting was the biggest cost and burnout source in US medicine. From 2023, LLM-based AI scribes cut that time by 90 %.

The differentiator for scribes is EMR-integration depth. Abridge runs deepest with Epic, Suki with Cerner and Athenahealth, and DAX Copilot has the deepest Epic integration. Physicians do not press a separate button during the visit — the recording happens in the background, the note is auto-generated, and a single click inserts it into the Epic chart.

Chapter 13 · Chronic Care Management — Omada, Livongo, Virta, Vida, Cecelia

Chronic-disease management is the highest cost-per-patient category in healthcare. A single diabetes, hypertension, or heart-failure patient costs over $10,000 a year.

The ROI calculation is simple. If a patient avoids one emergency room visit, $5,000-10,000 is saved. Coaching at $100 a month for a year is $1,200. The return profile is clear from a payer or employer point of view.

Chapter 14 · Korean Non-Face-to-Face Care — DoctorNow, Goodoc, Ttocdoc, Nemoya Doctor

Korean non-face-to-face care started on February 24, 2020 as a temporary allowance. It was upgraded to a pilot in June 2023, and the December 2024 Medical Service Act amendment cemented chronic-disease management and follow-up care.

The key points of the December 2024 amendment of the Medical Service Act:

The biggest unresolved issue in May 2026 is drug delivery. Unlike in Japan and the US, mailing prescription drugs is hard in Korea because of pharmacist association opposition. Patients still visit a pharmacy in person or get neighborhood-pharmacy matching with a quick-courier delivery.

Chapter 15 · Japanese Online Consultation — Linkx, LINE Healthcare, CLINIC FOR, MedPeer

Japan has moved through consistent step-by-step expansion, unlike Korea and the US. The April 2018 introduction of online-consultation reimbursement was followed by the April 2020 COVID-era expansion, the January 2022 main-provision elevation, and the April 2023 introduction of online prescriptions.

The April 2023 introduction of online prescriptions was a turning point. Until then, a patient who saw a doctor on video still had to visit a pharmacy or clinic to pick up a paper prescription. After enforcement, electronic prescriptions are sent directly to pharmacies and integrated into the patient's My Number Portal.

The differentiator in Japan compared with Korea and the US is the depth of physician-centric SNS networks. MedPeer has 140,000 members, and M3 Career has over 300,000. With patient and physician apps under one roof, there is less friction in prescription, billing, and booking.

Chapter 16 · European Telehealth — Doctolib, KRY/Livi, Babylon Health

Europe is yet another picture compared with the US and Asia. It is not a single market but the EU's 27 countries — a single market in many respects, but healthcare remains national sovereign territory. Within that, two companies took large positions.

Doctolib's strength is integrating booking and care. A patient searches a clinic and books, and the booking converts automatically into a video visit when needed. Deep EMR integration creates strong physician lock-in.

The Babylon bankruptcy illustrates the difficulty of the telehealth business. After a SPAC IPO in 2021 with a $3.6 billion market cap, NHS GP at Hand revenue-recognition disputes and a failed US push effectively wound the company down in 18 months.

Chapter 17 · AI Symptom Checkers — K Health, Ada, Buoy, Mediktor, Sensely

AI symptom checkers are the first-stage filter for telehealth entry. The patient enters symptoms before seeing a physician and receives possible diagnoses and a next-step recommendation.

The limit on symptom checkers is accuracy. A 2020 BMJ study put diagnostic hit rates at 33-50 % and triage-recommendation accuracy at 55-80 % for major checkers. They are closer to a primary triage aid than a true diagnostic tool.

Since 2023, LLMs like GPT-4, Med-PaLM 2, and Claude have begun threatening the symptom checker category directly. Microsoft and Google are likely to roll out ChatGPT-style medical chatbots as integrated medical services.

Chapter 18 · AI Insurance and Eligibility Automation — Olive, Cohere Health, Notable

Next to telehealth, medical administration automation grew alongside the AI era.

The Olive AI wind-down shows the difficulty of AI in healthcare. Even when the technology works, integration into the healthcare system — EMRs, payer APIs, HIPAA compliance — is extraordinarily expensive. Cohere survived by focusing on a single area (prior authorization) and locking down payer channels.

Chapter 19 · Prescription Drug Delivery — Capsule, Alto, Amazon Pharmacy, Truepill

The last mile of telehealth is drug delivery. Video visit → prescription → pharmacy → into the patient's hands. The companies integrating that flow in a single app.

Prescription delivery is the last vertical-integration piece in telehealth. The patient should have the medication in hand within 30 minutes of the visit for the video-visit value to be complete. Hims, Ro, and Capsule are all moving in that direction.

Chapter 20 · Wearable Integration — Whoop, Oura, Apple Watch, Garmin, Dexcom

Wearables sit at the center of chronic-care and everyday health monitoring. The iter91 guide covered them separately, but here we touch on their telehealth integration.

CGM (continuous glucose monitoring) is at the core of chronic-disease management. Dexcom and Abbott Libre are reimbursed by prescription, while non-prescription lines (Lingo, Stelo, Dexcom G7) target the general consumer market.

Chapter 21 · Regulation — HIPAA, Korea PIPA, Japan APPI, EU GDPR, DEA Final Rule

Regulation is the biggest constraint on telehealth. Patient information, prescriptions, physician licensing, and drug delivery are all regulated.

Regulatory differences make market differences. The US allows free DTC telehealth but strictly regulates controlled-substance prescribing. Korea has blocked drug delivery. Japan's step-by-step expansion has been stable. The EU shoulders the GDPR burden but has consistent medical-data governance.

Chapter 22 · AI Medical Ethics — Diagnostic Responsibility, Bias, Patient Consent

AI's entry into medicine has surfaced new ethical questions.

In 2024-2025, the FDA approved about 1,000 AI/ML-based medical devices. Imaging diagnostics (chest X-ray, MRI), ECG analysis, and retinal (fundus) diagnostics are the mainstream. Clinical Decision Support AI sits under separate guidance.

Chapter 23 · Real Scenarios — Chronic, Mental Health, Primary Care, Pediatric

The 70-plus services covered in this article bundled into user scenarios.

[Scenario A — US primary care + GLP-1]
  1. User requests weight-management care in the Hims & Hers app
  2. Physician video visit → prescription
  3. Truepill / in-house pharmacy → home delivery
  4. Daily monitoring via Whoop or Apple Watch
  5. 24-hour chat support for side effects

[Scenario B — Korean chronic care (hypertension, diabetes)]
  1. Search and book a neighborhood clinic in the DoctorNow app
  2. Video or phone non-face-to-face care (chronic follow-up allowed)
  3. Prescription issued → neighborhood-pharmacy matching → quick-courier delivery
  4. Share Dexcom G7 or Abbott Libre CGM data with the doctor

[Scenario C — Japan primary care + prescription]
  1. Book a physician on Curon or CLINIC FOR
  2. Video visit
  3. Online prescription → direct pharmacy transmission
  4. Patient gets home delivery or pharmacy pickup

[Scenario D — US psychiatry + AI scribe]
  1. In-network psychiatrist match on Talkiatry
  2. Abridge records in the background during the visit
  3. Physician inserts AI note into the Epic chart in one click after the visit
  4. Prescription delivered by Capsule or Amazon Pharmacy
  5. BetterHelp or Talkspace for supplementary therapy

[Scenario E — US pediatric mental health]
  1. Adolescent ADHD care via the Brightline app
  2. Parent guardian consent → video visit
  3. ADHD meds (Schedule II) — at least one in-person visit per DEA Final Rule
  4. Coordination with school counselors and pediatricians

Each scenario uses a different mix of services. The stages where AI creates the most value are triage, note-taking, and daily monitoring. The final diagnosis and prescription decisions stay with physicians.

Chapter 24 · Economics — Where Does Telehealth ROI Come From

The economics of telehealth are measured on three axes.

Market caps of listed telehealth companies as of May 2026:

Hims & Hers' surge has two drivers. (1) Compounded GLP-1, and (2) the simple revenue recognition of a DTC model that bypasses insurance. Conversely, Teladoc and Amwell are heavily dependent on payer channels, with long revenue cycles and low ARPU per patient.

Chapter 25 · Conclusion — The Next Six Years of Telehealth

2020-2026 was the explosion-and-normalization cycle for telehealth. Three big themes for the next six years (2026-2032).

Telehealth claims that grew 154-fold in a single month in 2020 settled at about 38 times pre-pandemic levels in 2026 (CMS data). Remote care has not replaced in-person, but it has become the standard for medical entry and chronic-disease management.

The winners of the next six years are the firms that capture (1) AI integration depth, (2) payer and employer channel stability, and (3) the last-mile of drug delivery — all at once.

References

This article is current as of May 18, 2026. Telehealth pricing, features, and regulations change rapidly. Clinical decisions must always follow the judgment of physicians, pharmacists, and licensed professionals.

Comments

No comments yet.

Sign in to leave a comment